DeepMed Research

Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms

Phase 2

Active, not recruiting

Conditions: Scleroderma, Systemic

Interventions: Drug: Avenciguat (BI 685509)
Drug: Placebo

First Posted Date: 2022-09-29

Last Posted Date: 2025-01-30

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 188

Registration Number: NCT05559580

Locations: 🇯🇵
Nippon Medical School Hospital, Tokyo, Bunkyo-ku, Japan
🇷🇴
St. Mary's Clinical Hospital, Bucharest, Romania
🇷🇴
Dr. Ion Cantacuzino Clinical Hospital, Bucharest, Bucharest, Romania

and more 162 locations

A Study in Healthy Men to Test Whether BI 1015550 Influences the Amount of Midazolam in the Blood

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1015550
Drug: midazolam

First Posted Date: 2022-09-22

Last Posted Date: 2022-12-21

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 15

Registration Number: NCT05550636

Locations: 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany

A Study in Europe Based on Medical Records That Looks at the Safety of Dabigatran in Children Below 2 Years of Age Who Have Had a Blood Clot and Are at Risk of Developing Another Blood Clot

Withdrawn

Conditions: Venous Thromboembolism

Interventions: Drug: Dabigatran Etexilate (DE)

First Posted Date: 2022-09-13

Last Posted Date: 2024-06-26

Lead Sponsor: Boehringer Ingelheim

Registration Number: NCT05536791

Locations: 🇩🇪
Charité - Universitätsmedizin Berlin, Berlin, Germany
🇳🇱
Radboud Universitair Medisch Centrum, Nijmegen, Netherlands
🇪🇸
Hospital Sant Joan de Déu, Barcelona, Spain

and more 3 locations

A Study in Healthy Men to Test How Different Doses of BI 1584862 Are Tolerated and How BI 1584862 is Taken up in the Body With or Without Food

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1584862
Drug: Placebo

First Posted Date: 2022-08-30

Last Posted Date: 2023-03-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 77

Registration Number: NCT05520827

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

A Study in Healthy Men to Test How Different Doses of BI 3032950 Are Tolerated

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 3032950
Drug: Placebo

First Posted Date: 2022-08-29

Last Posted Date: 2023-09-26

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 94

Registration Number: NCT05518708

Locations: 🇧🇪
SGS Life Science Services - Clinical Research, Edegem, Belgium

A Study in Healthy Men to Test How BI 690517 is Taken up and Handled by the Body

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 690517 (C-14)
Drug: BI 690517

First Posted Date: 2022-08-25

Last Posted Date: 2022-11-21

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 14

Registration Number: NCT05515588

Locations: 🇳🇱
ICON, Groningen, Netherlands

A Study in Healthy Men to Test How BI 685509 is Processed in the Body

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: [¹⁴C] BI 685509 formulation 1
Drug: [¹⁴C] BI 685509 formulation 2
Drug: BI 685509 formulation 3

First Posted Date: 2022-08-25

Last Posted Date: 2022-11-28

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 12

Registration Number: NCT05515328

Locations: 🇳🇱
ICON, Groningen, Netherlands

Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder

Phase 2

Active, not recruiting

Conditions: Pancreatic Neoplasms
Lung Neoplasms
Solid Tumors
Biliary Tract Cancer
Bladder Cancer

Interventions: Drug: brigimadlin

First Posted Date: 2022-08-23

Last Posted Date: 2025-05-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 99

Registration Number: NCT05512377

Locations: 🇺🇸
Southern Cancer Center, Mobile, Alabama, United States
🇺🇸
University of Arizona, Tucson, Arizona, United States
🇺🇸
University of Southern California, Los Angeles, California, United States

and more 57 locations

Correlation Between Changes in Lung Function and Changes in Cough and Dyspnoea in Nintedanib-treated Connective Tissue Disease Interstitial Lung Disease (CTD-ILD) Patients

Active, not recruiting

Conditions: Lung Diseases, Interstitial

Interventions: Drug: Nintedanib

First Posted Date: 2022-08-16

Last Posted Date: 2025-01-10

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 87

Registration Number: NCT05503030

Locations: 🇬🇷
Clinic "Agios Loukas", Thessaloniki, Greece
🇬🇷
Private physician, Thessaloniki, Greece
🇬🇷
"G. Gennimatas" General Hospital of Athens, Athens, Greece

and more 10 locations

Exacerbation Risk in Asthma

Completed

Conditions: Asthma

Interventions: Drug: long-acting β2-agonists (LABA)
Drug: tiotropium
Drug: inhaled corticosteroids (ICS)

First Posted Date: 2022-08-15

Last Posted Date: 2024-04-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1899

Registration Number: NCT05501639

Locations: 🇺🇸
eMax Health, White Plains, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy